Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - MicardisPlus(R) - Hypertonie (38 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 31: Hypertonie - Behandlung Abb. 32: Antihypertensiva - Nebenwirkung Abb. 33: Hypertonie - Behandlung Aktuelles Bild - Abb. 34: Antihypertensiva- Eigenschaften Abb. 35: Hypertonie - Behandlung - Richtlinien Abb. 36: Hypertonie - Behandlung - Zwingende Indikationen Abb. 37: Angiotensin-I-Rezeptorblocker - Einsatzbereich Zum letzten Bild
Abbildung 34: Antihypertensiva- Eigenschaften
Blockade of the renin–angiotensin–aldosterone system (RAAS) is a potent way to reduce hypertension, and the RAAS forms a target for modern antihypertensive therapy.1 Patient compliance with antihypertensive medication is significantly improved if it requires only once-daily administration.2 Increased compliance, coupled with a 24-h efficacy, may be expected to improve patient outcomes. The ideal antihypertensive should also provide round-the-clock activity, especially in the early morning hours when blood pressure increases and cardiovascular events are at their most frequent.3 As with any drug, the therapeutic objectives should be achieved with a minimum of side effects. 1. Weinen W, et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardivasc Drug Rev 2000; 18: 127–156. 2. Iskedjian M, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002; 23: 302–316. 3. Mulcahy D. Circadian variation in cardiovascular events. Blood Press Monit 1998; 3: 29–34.
 
Antihypertensiva- Eigenschaften
Vorheriges Bild Nächstes Bild   


Abbildung 34: Antihypertensiva- Eigenschaften
Blockade of the renin–angiotensin–aldosterone system (RAAS) is a potent way to reduce hypertension, and the RAAS forms a target for modern antihypertensive therapy.1 Patient compliance with antihypertensive medication is significantly improved if it requires only once-daily administration.2 Increased compliance, coupled with a 24-h efficacy, may be expected to improve patient outcomes. The ideal antihypertensive should also provide round-the-clock activity, especially in the early morning hours when blood pressure increases and cardiovascular events are at their most frequent.3 As with any drug, the therapeutic objectives should be achieved with a minimum of side effects. 1. Weinen W, et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardivasc Drug Rev 2000; 18: 127–156. 2. Iskedjian M, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002; 23: 302–316. 3. Mulcahy D. Circadian variation in cardiovascular events. Blood Press Monit 1998; 3: 29–34.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung